drugset
drugset / Trial / NCT06932471

Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

NCT06932471 ↗

Phase 3 Recruiting 20 enrolled Wuhan Createrna Science and Technology Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the efficacy of MY008211A in PNH patients with residual anemia despite treatment with anti-C5 antibody.

Timeline

Start
2024-08-30
Primary completion
2025-12-30
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject MY008211A Unknown 400 mg Oral

Indications

paroxysmal nocturnal hemoglobinuria